- AbCellera acquires TetraGenetics in an all-cash transaction that includes up front, milestones based on the achievement of technical milestones related to the development of therapeutics
- The acquisition will combine TetraGenetics’ capabilities with AbCellera’s technology to provides an optimized protein source for AbCellera’s Abs discovery across a range of therapeutic areas. The technology has the potential to unlock the discovery of Abs against validated and drug targets
- TetraGenetics offers a protein expression platform that generates recombinant human ion channels, GPCR, and other transmembrane proteins to support Ab discovery
Click here to read full press release/ article | Ref: AbCellera | Image: AbCellera
The post AbCellera Acquires TetraGenetics to Enhance its Capabilities for Developing Antibodies first appeared on PharmaShots.